Full-Time

Director – Trade and Distribution

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$210k - $253kAnnually

Senior, Expert

San Carlos, CA, USA

Position based out of headquarters in Redwood City, CA.

Category
Supply Chain Management
Operations & Logistics
Requirements
  • Bachelor’s degree required with 7-8+ years of experience in market access operations in pharmaceuticals or biopharma.
  • Experience in new product launches.
  • Experience with day-to-day management of 3PL and other distribution partners.
  • Deep understanding of US drug channel dynamics.
  • Experience with 844/867/852 data and inventory reporting and systems.
  • Track record of being a collaborative team player, and adaptive to meet the needs of a growing business.
  • Strong problem solver with experience leveraging a variety of data sources, platforms, and analytical vendors.
  • Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines.
  • Ability to represent Revolution Medicines well: strong interpersonal skills including verbal and written communication.
  • Ability to travel up to 25%.
Responsibilities
  • Establishes and manage strong relationships with key distribution partners, including 3PL vendor, specialty distributors, and specialty pharmacies.
  • Oversees 3PL vendor.
  • Coordinates across Supply Chain, Information Systems (IS), Quality, Finance and Commercial to prepare for launching RevMed’s first medicine, including initial stocking plan and distribution data strategy.
  • Partners closely with Finance and government pricing vendor to ensure shipment data, chargebacks, and returns are correctly loaded in internal data reporting systems.
  • Partners with finance to review chargebacks for accuracy and eligibility in accordance with contract terms.
  • Develops return policy and approve returns that meet policy requirements once product launches.
  • Leads regular business reviews with distribution partners to ensure KPIs and service level agreements (SLAs) are being met and identify opportunities to improve processes.
  • Works with Sr. Director to refine the distribution strategy if needed for any future approved indication(s) and/or new product launches.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Shift towards personalized medicine aligns with their focus on genetic mutations.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' market strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?